Assembly Biosciences (ASMB) Payables (2010 - 2026)

Assembly Biosciences' Payables history runs 17 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Payables rose 29.03% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 29.03% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 100.17% from the prior year.
• Payables declined to $1.1 million in Q1 2026 per ASMB's latest filing, from $1.2 million in the prior quarter.
• Across five years, Payables topped out at $2.5 million in Q4 2022 and bottomed at $461000.0 in Q4 2023.
• The 5-year median for Payables is $1.1 million (2026), against an average of $1.2 million.
• Across the five-year window, Payables sank 81.51% in 2023 and soared 100.17% in 2025, its largest moves.
• Year by year, Payables stood at $2.5 million in 2022, then tumbled by 81.51% to $461000.0 in 2023, then climbed by 26.9% to $585000.0 in 2024, then surged by 100.17% to $1.2 million in 2025, then retreated by 3.59% to $1.1 million in 2026.
• Per Business Quant, the three latest ASMB Payables figures stand at $1.1 million (Q1 2026), $1.2 million (Q4 2025), and $1.7 million (Q3 2025).